The Longevity Formula — Built on Published Research

This formula's 500 mg amount was not tested in the trial we cite: that single randomized, double-blind, placebo-controlled trial (PMID 36482258, n=80 healthy middle-aged adults) compared 300, 600, and 900 mg NMN daily with placebo and found all three doses significantly raised blood NAD concentrations and improved six-minute walking distance over 60 days, with the highest values at 600 and 900 mg. (PMID 36482258)

A 2015 randomized crossover study (PMID 26226960, n=29) found 20 mg/day PQQ disodium salt reduced LDL cholesterol and trended toward improved metabolic markers over 12 weeks in healthy adults; Micro PQQ is disodium PQQ at pharmaceutical-grade purity. (PMID 26226960)

A 2013 safety and dose-ranging trial (PMID 23431291, n=80) used 50–250 mg/day pterostilbene over 6–8 weeks and found no adverse hepatic, renal, or glucose markers; 100 mg/day represents a midpoint maintenance dose with established tolerability data. (PMID 23431291)

A 12-year follow-up of a randomized trial (PMID 29641571) found that 200 mg/day CoQ10 combined with selenium over 4 years produced sustained cardiovascular mortality reduction. Ubiquinone is the more chemically stable of the two CoQ10 redox forms. (PMID 29641571)

Fisetin has been studied primarily as a pulsed senolytic. Continuous low-dose use at 100 mg/day is provisional — data is emerging and this dose is listed without confirmed efficacy claims for continuous use.

A 2018 Phase II safety and tolerability trial (PMID 29315079, n=30 older adults with subjective cognitive decline) found 1.2 mg/day spermidine, given as a spermidine-rich wheat germ extract, was well tolerated over 3 months; that trial did not test spermidine-3HCl. By molecular weight, 1.75 mg of spermidine-3HCl contains approximately 1 mg free spermidine. (PMID 29315079)

A 2024 randomized three-way crossover study (PMID 39781273, n=21) found AvailOm®'s L-lysine salt FFA form delivered 9.3× higher EPA+DHA absorption than ethyl ester and 1.57× higher than triglyceride form over 12 hours; the FFA-bound form is selected for superior blood-level response. (PMID 39781273)

A single 2020 randomized, double-blind, placebo-controlled trial (PMID 32512782, n=80) found 400 mg LONGVIDA® daily (providing 80 mg curcumin) improved working memory at 12 weeks and reduced fatigue at 4 and 12 weeks in healthy older adults aged 50–80; the same trial also reported significantly elevated blood glucose in the curcumin group. (PMID 32512782)

A 7-year observational study of oral dosing (PMID 30611908) found 5000 IU/day cholecalciferol to be safe in long-term use and effective at achieving target 25(OH)D levels; D3 is the form the skin synthesizes from sunlight. (PMID 30611908)

Magnesium oxide has approximately 4% fractional absorption in controlled studies (PMID 11794633); bisglycinate chelate forms are selected for improved absorption and tolerability over oxide. Albion® chelates are the reference standard. (PMID 11794633)